Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Short Interest Down 9.6% in April

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 1,980,000 shares, a decrease of 9.6% from the March 31st total of 2,190,000 shares. Based on an average daily volume of 354,100 shares, the days-to-cover ratio is currently 5.6 days.

Institutional Trading of Actinium Pharmaceuticals

Several large investors have recently bought and sold shares of ATNM. Brandywine Global Investment Management LLC acquired a new position in shares of Actinium Pharmaceuticals during the 3rd quarter valued at about $1,033,000. Creative Financial Designs Inc. ADV increased its stake in Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 3,175 shares during the last quarter. Finally, Sanders Morris Harris LLC purchased a new stake in Actinium Pharmaceuticals in the first quarter valued at $78,000. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Performance

Actinium Pharmaceuticals stock traded up $0.51 during trading hours on Monday, hitting $7.38. 244,842 shares of the stock traded hands, compared to its average volume of 322,240. Actinium Pharmaceuticals has a 1 year low of $4.00 and a 1 year high of $9.86. The company has a market cap of $216.97 million, a PE ratio of -4.06 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.21. The firm had revenue of $0.08 million for the quarter. As a group, analysts predict that Actinium Pharmaceuticals will post -1.87 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ATNM. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, March 19th. Maxim Group upped their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Actinium Pharmaceuticals in a research report on Monday. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.72.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.